CD28/B7 system of T cell costimulation.
暂无分享,去创建一个
[1] S. Korsmeyer,et al. Apoptotic death of lymphocytes in murine acquired immunodeficiency syndrome: Involvement of Fas‐Fas ligand interaction , 1995, European journal of immunology.
[2] R. Karr,et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. , 1995, Journal of immunology.
[3] J. Allison,et al. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.
[4] B Zheng,et al. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. , 1995, Journal of immunology.
[5] C. Thompson,et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.
[6] D. Loh,et al. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. , 1995, Journal of immunology.
[7] R. Karr,et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. , 1995, The Journal of clinical investigation.
[8] J. Gribben,et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. , 1995, Immunity.
[9] G. Forni,et al. Co‐expression of B7‐1 and ICAM‐1 on tumors is required for rejection and the establishment of a memory response , 1995, European journal of immunology.
[10] P. Linsley,et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2 , 1995, The Journal of experimental medicine.
[11] L. Chen,et al. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. , 1995, Journal of immunology.
[12] Laurie H Glimcher,et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.
[13] J. Bluestone,et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.
[14] P. Albert,et al. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. , 1995, Journal of immunology.
[15] J. Ceuppens,et al. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. , 1995, International immunology.
[16] P. Linsley,et al. Studies on the interdependence of gp39 and B7 expression and function during antigen‐specific immune responses , 1995, European journal of immunology.
[17] C. June,et al. CD28 activation promotes Th2 subset differentiation by human CD4+ cells , 1995, European journal of immunology.
[18] J. Gribben,et al. CTLA4 mediates antigen-specific apoptosis of human T cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[19] H. Weiner,et al. Reciprocal expression of co‐stimulatory molecules, B7‐1 and B7‐2, on murine T cells following activation , 1995, European journal of immunology.
[20] P. Linsley,et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. , 1995, Journal of immunology.
[21] N. Perico,et al. Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. , 1995, Kidney international.
[22] J. Allison,et al. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. , 1994, Cancer research.
[23] P. Linsley,et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.
[24] P. Linsley,et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1 , 1994, The Journal of experimental medicine.
[25] P. Linsley,et al. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. , 1994, Journal of immunology.
[26] R. Steinman,et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro , 1994, The Journal of experimental medicine.
[27] P. Linsley,et al. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. , 1994, Transplantation.
[28] M. Cooke,et al. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. , 1994, Journal of immunology.
[29] C. S. Campbell,et al. REJECTION IN HEART TRANSPLANTATION STRONGLY CORRELATES WITH HLA‐DR ANTIGEN MISMATCH , 1994, Transplantation.
[30] J. Bluestone,et al. Absence of B7-dependent responses in CD28-deficient mice. , 1994, Immunity.
[31] R. Noelle,et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. , 1994, Immunology today.
[32] P. Linsley,et al. Treatment of murine lupus with CTLA4Ig. , 1994, Science.
[33] P. Linsley,et al. CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.
[34] G. Freeman,et al. A negative regulatory function of B7 revealed in B7-1 transgenic mice. , 1994, Immunity.
[35] P. Linsley,et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.
[36] P. Linsley,et al. CTLA-4 ligands are required to induce an in vivo interleukin 4 response to a gastrointestinal nematode parasite , 1994, The Journal of experimental medicine.
[37] J. Bluestone,et al. The B7 and CD28 receptor families. , 1994, Immunology today.
[38] D. Loh,et al. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. , 1994, Immunity.
[39] Lieping Chen,et al. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. , 1994, Journal of immunology.
[40] P. Linsley,et al. Transplantation tolerance induced by CTLA4-Ig. , 1994, Transplantation.
[41] P. Linsley,et al. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. , 1994, Blood.
[42] H. Ochs,et al. Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. , 1994, Journal of immunology.
[43] J. Bluestone,et al. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. , 1994, Journal of immunology.
[44] P. Linsley,et al. Effect of CTLA‐4 chimeric protein on rat autoimmune anti‐glomerular basement membrane glomerulonephritis , 1994, European journal of immunology.
[45] P. Linsley,et al. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[46] L. Shen,et al. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. , 1994, Journal of immunology.
[47] N. Nabavi,et al. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. , 1994, Immunity.
[48] R. Flavell,et al. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. , 1994, Immunity.
[49] M P Cooke,et al. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells , 1994, The Journal of experimental medicine.
[50] D. Harlan,et al. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[51] M. Goldman,et al. Interleukin‐10 inhibits B7 and intercellular adhesion molecule‐1 expression on human monocytes , 1994, European journal of immunology.
[52] Y. Wu,et al. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells , 1994, The Journal of experimental medicine.
[53] P. Linsley,et al. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. , 1994, Journal of immunology.
[54] G. Powers,et al. Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. , 1994, Journal of immunology.
[55] B. Hausmann,et al. Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo , 1994, The Journal of experimental medicine.
[56] P. Lane,et al. B cell function in mice transgenic for mCTLA4-H gamma 1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4+ T cells , 1994, The Journal of experimental medicine.
[57] J. Johnston,et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.
[58] P. Linsley,et al. CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production , 1994, The Journal of experimental medicine.
[59] J. Ceuppens,et al. Ligation of B7 with CD28/CTLA‐4 on T cells results in CD40 ligand expression, interleukin‐4 secretion and efficient help for antibody production by B cells , 1993, European journal of immunology.
[60] J. Bluestone,et al. Expression and functional significance of an additional ligand for CTLA-4. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[61] H. Reiser,et al. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[62] J. Gribben,et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production , 1993, The Journal of experimental medicine.
[63] G. Freeman,et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. , 1993, Science.
[64] J. Gribben,et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.
[65] P. Linsley,et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. , 1993, Science.
[66] L. Lanier,et al. B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.
[67] P. Linsley,et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion , 1993, The Journal of experimental medicine.
[68] Y. Wu,et al. A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7 , 1993, The Journal of experimental medicine.
[69] J. Mcarthur,et al. CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4 , 1993, The Journal of experimental medicine.
[70] G. Freeman,et al. Characterization of CTLA-4 structure and expression on human T cells. , 1993, Journal of immunology.
[71] V. Stewart,et al. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. , 1993, Science.
[72] C. Thompson,et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.
[73] P. Linsley,et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. , 1993, Journal of immunology.
[74] K P Lee,et al. Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.
[75] G. Freeman,et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[76] K. Lafferty,et al. The maintenance of self‐tolerance , 1993, Immunology and cell biology.
[77] P. Linsley,et al. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. , 1993, Journal of immunology.
[78] T. Kipps,et al. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.
[79] P. Linsley,et al. Induction of costimulatory molecule B7 in M12 B lymphomas by cAMP or MHC-restricted T cell interaction. , 1993, Journal of immunology.
[80] P. Linsley,et al. Expression and function of B7 on human epidermal Langerhans cells. , 1993, Journal of immunology.
[81] J. Allison,et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.
[82] C Anasetti,et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 , 1993, The Journal of experimental medicine.
[83] P. Linsley,et al. The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.
[84] P. Linsley,et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.
[85] G. Freeman,et al. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. , 1992, Journal of immunology.
[86] P. Linsley,et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes , 1992, The Journal of experimental medicine.
[87] G. Freeman,et al. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression , 1992, Nature.
[88] P. Linsley,et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[89] P. Linsley,et al. Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations , 1992, The Journal of experimental medicine.
[90] P. Linsley,et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.
[91] P. Linsley,et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. , 1992, Science.
[92] J. Allison,et al. Identification and distribution of the costimulatory receptor CD28 in the mouse. , 1992, Journal of immunology.
[93] P. Linsley,et al. Costimulation of T-cell growth. , 1992, Current opinion in immunology.
[94] C. van Kooten,et al. Interleukin (IL)‐4 production by human T cells: differential regulation of IL‐4 vs. IL‐2 production , 1992, European journal of immunology.
[95] J. Allison,et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.
[96] L. Lanier,et al. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes , 1992, The Journal of experimental medicine.
[97] G. Freeman,et al. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. , 1991, Cellular immunology.
[98] J. Gribben,et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7 , 1991, The Journal of experimental medicine.
[99] M. Mattei,et al. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. , 1991, Journal of immunology.
[100] J. Gribben,et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[101] J. Banchereau,et al. IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. , 1991, International immunology.
[102] P. Linsley,et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.
[103] R. Schreiber,et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.
[104] P. Linsley,et al. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[105] J. Allison,et al. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. , 1990, Journal of immunology.
[106] C. Thompson,et al. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. , 1990, Journal of immunology.
[107] P. Linsley,et al. Role of the CD28 receptor in T-cell activation. , 1990, Immunology today.
[108] G. Freeman,et al. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. , 1989, Journal of immunology.
[109] C. Thompson,et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[110] F. Denizot,et al. A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.
[111] W. Lesslauer,et al. Biochemical characterization of the 9.3 antigens of human T-cells: simultaneous expression of disulfide-bonded 90-kilodalton dimers and free subunits at the cell surface. , 1986, Molecular immunology.
[112] T. Yokochi,et al. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. , 1982, Journal of immunology.
[113] Melvin Cohn,et al. A Theory of Self-Nonself Discrimination , 1970, Science.